[go: up one dir, main page]

PE20040534A1 - Medicamentos que comprenden tiofenos sustituidos y procedimientos para su preparacion - Google Patents

Medicamentos que comprenden tiofenos sustituidos y procedimientos para su preparacion

Info

Publication number
PE20040534A1
PE20040534A1 PE2003000531A PE2003000531A PE20040534A1 PE 20040534 A1 PE20040534 A1 PE 20040534A1 PE 2003000531 A PE2003000531 A PE 2003000531A PE 2003000531 A PE2003000531 A PE 2003000531A PE 20040534 A1 PE20040534 A1 PE 20040534A1
Authority
PE
Peru
Prior art keywords
methyl
thiophenes
procedures
preparation
alkyl
Prior art date
Application number
PE2003000531A
Other languages
English (en)
Inventor
Markus Bleich
Michael Gekle
Klaus Wirth
Armin Hofmeister
Hans-Jochen Lang
Uwe Heinelt
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PE20040534A1 publication Critical patent/PE20040534A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41681,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE R1 Y R2 SON CADA UNO H, F, Cl, CN, ENTRE OTROS; R3 ES H, METILO, HALOGENO, CN, ENTRE OTROS; R4 ES H, CICLOALQUILO C3-C6, ALQUENILO C2-C4, ENTRE OTROS; R5 Y R6 SON H O, JUNTOS, UN ENLACE; R7 Y R8 SON CADA UNO ALQUILO C3-C5, ALQUENILO C2-C5, ALQUINILO C2-C5, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: TRANS-R,R-2-CLORO-3N-(3a,4,5,6,7,7a-HEXAHIDRO-1H-2-BENCIMIDAZOLIL)-4-METIL-3-TIENILAMINA; TRANS-R,R-2-BROMO-3N-(3a,4,5,6,7,7a-HEXAHIDRO-1H-2-BENCIMIDAZOLIL)-4-METIL-3-TIENILAMINA Y 2-CLORO-3N-(2-BENCIMIDAZOLIL)-4-METIL-3-TIENILAMINA. SE REFIERE TAMBIEN A UN MEDICAMENTO. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE TRANSTORNOS RESPIRATORIOS (APNEA DEL SUENO, RONQUIDOS), DE PRESION SANGUINEA ALTA, DE PARASITOSIS Y PROFILAXIS DE TRASTORNOS DEL SNC Y DEL METABOLISMO DE LIPIDOS
PE2003000531A 2002-06-04 2003-05-30 Medicamentos que comprenden tiofenos sustituidos y procedimientos para su preparacion PE20040534A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10224892A DE10224892A1 (de) 2002-06-04 2002-06-04 Substituierte Thiophene, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (1)

Publication Number Publication Date
PE20040534A1 true PE20040534A1 (es) 2004-10-25

Family

ID=29557542

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000531A PE20040534A1 (es) 2002-06-04 2003-05-30 Medicamentos que comprenden tiofenos sustituidos y procedimientos para su preparacion

Country Status (32)

Country Link
EP (1) EP1513834B1 (es)
JP (1) JP4511924B2 (es)
KR (1) KR101087966B1 (es)
CN (1) CN1324024C (es)
AR (1) AR040239A1 (es)
AT (1) ATE320425T1 (es)
AU (1) AU2003273553B2 (es)
BR (1) BR0311548A (es)
CA (1) CA2488242C (es)
CR (1) CR7577A (es)
DE (2) DE10224892A1 (es)
DK (1) DK1513834T3 (es)
EC (1) ECSP045471A (es)
ES (1) ES2258722T3 (es)
HR (1) HRP20041153A2 (es)
IL (1) IL165519A (es)
MA (1) MA27204A1 (es)
ME (1) MEP27608A (es)
MX (1) MXPA04011986A (es)
MY (1) MY129832A (es)
NO (1) NO329351B1 (es)
OA (1) OA12827A (es)
PE (1) PE20040534A1 (es)
PL (1) PL372589A1 (es)
PT (1) PT1513834E (es)
RS (1) RS51141B (es)
RU (1) RU2315766C2 (es)
TN (1) TNSN04240A1 (es)
TW (1) TWI283675B (es)
UA (1) UA77551C2 (es)
WO (1) WO2003101984A1 (es)
ZA (1) ZA200409095B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10323701A1 (de) 2003-05-22 2004-12-23 Aventis Pharma Deutschland Gmbh Verfahren zur Synthese heterocyclischer Verbindungen
US20040242560A1 (en) 2003-05-22 2004-12-02 Aventis Pharma Deutschland Gmbh Process for synthesizing heterocyclic compounds
ES2545903T3 (es) 2003-06-30 2015-09-16 Sumitomo Chemical Company, Limited Compuestos de urea asimétricos y procedimiento para producir compuestos asimétricos por reacción de adición asimétrica de conjugado usando dichos compuestos como catalizador
JP2010507664A (ja) * 2006-10-25 2010-03-11 武田薬品工業株式会社 ベンズイミダゾール化合物
BRPI0918502A2 (pt) 2008-09-02 2015-12-01 Sanofi Aventis aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos
RU2373929C1 (ru) * 2008-11-11 2009-11-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) Корректор системы гемостаза, проявляющий ингибирующее действие на адгезивно-агрегационную функцию тромбоцитов для профилактики патологического тромбообразования
CN102712601A (zh) * 2009-11-12 2012-10-03 赛尔维他股份公司 化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂
RU2518740C1 (ru) * 2013-03-22 2014-06-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" СРЕДСТВО, ИНГИБИРУЮЩЕЕ Na+/H+-ОБМЕН, И ДИГИДРОХЛОРИД 2-(3,4-МЕТИЛЕНДИОКСИФЕНИЛ)-9-МОРФОЛИНОЭТИЛИМИДАЗО[1,2-a]БЕНЗИМИДАЗОЛА
KR102386666B1 (ko) 2014-07-25 2022-04-15 다이쇼 세이야꾸 가부시끼가이샤 헤테로아릴로 치환된 페닐테트라히드로이소퀴놀린 화합물
KR102840252B1 (ko) * 2023-04-27 2025-07-30 한국화학연구원 시아노벤즈이미다졸 유도체, 약제학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
CN120112529B (zh) * 2023-09-28 2026-01-06 四川大学华西医院 一种含吡啶的化合物及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754935A (fr) * 1969-08-13 1971-02-17 Hoechst Ag 2-(thienyl-3'-amino)-1,3-diazacycloalcenes et leur preparation
BR6915362D0 (pt) * 1969-08-16 1973-01-04 Hoechst Ag Processo para a preparacao de 2(tienil-3-amino)1,3-diazacicloalquenos
DE2830279A1 (de) * 1978-07-10 1980-01-31 Boehringer Sohn Ingelheim 2-eckige klammer auf n-(2'-chlor-4'- methyl-thienyl-3')-n-(cyclopropylmethyl)- amino eckige klammer zu-imidazolin-(2), dessen saeureadditionssalze, dieses enthaltende arzneimittel und verfahren zu seiner herstellung
US5395847A (en) * 1993-12-02 1995-03-07 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
AU747784B2 (en) * 1998-07-29 2002-05-23 Merck & Co., Inc. Integrin receptor antagonists
DE19921883A1 (de) * 1999-05-12 2000-11-16 Bayer Ag Substituierte Thienocycloalk(en)ylamino-1,3,5-triazine
DE19960204A1 (de) * 1999-12-14 2001-06-28 Aventis Pharma Gmbh Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US7071216B2 (en) * 2002-03-29 2006-07-04 Chiron Corporation Substituted benz-azoles and methods of their use as inhibitors of Raf kinase

Also Published As

Publication number Publication date
IL165519A0 (en) 2006-01-15
EP1513834A1 (de) 2005-03-16
IL165519A (en) 2010-05-31
KR101087966B1 (ko) 2011-12-01
JP2005533038A (ja) 2005-11-04
CN1324024C (zh) 2007-07-04
HK1076460A1 (en) 2006-01-20
ECSP045471A (es) 2005-01-28
MXPA04011986A (es) 2005-03-07
MA27204A1 (fr) 2005-01-03
RS51141B (sr) 2010-10-31
CA2488242C (en) 2011-08-02
AU2003273553A1 (en) 2003-12-19
NO329351B1 (no) 2010-10-04
RU2004138812A (ru) 2005-07-20
TWI283675B (en) 2007-07-11
AR040239A1 (es) 2005-03-23
TNSN04240A1 (en) 2007-03-12
OA12827A (en) 2006-07-11
CR7577A (es) 2005-06-16
ZA200409095B (en) 2005-05-10
DE10224892A1 (de) 2003-12-18
HRP20041153A2 (en) 2005-06-30
PT1513834E (pt) 2006-06-30
UA77551C2 (en) 2006-12-15
PL372589A1 (en) 2005-07-25
ATE320425T1 (de) 2006-04-15
WO2003101984A1 (de) 2003-12-11
KR20050005532A (ko) 2005-01-13
TW200406409A (en) 2004-05-01
RS103804A (sr) 2006-12-15
AU2003273553B2 (en) 2008-12-04
MY129832A (en) 2007-05-31
JP4511924B2 (ja) 2010-07-28
DK1513834T3 (da) 2006-07-17
DE50302673D1 (de) 2006-05-11
EP1513834B1 (de) 2006-03-15
BR0311548A (pt) 2005-04-12
MEP27608A (en) 2010-06-10
ES2258722T3 (es) 2006-09-01
NO20045504L (no) 2005-01-25
CN1659163A (zh) 2005-08-24
RU2315766C2 (ru) 2008-01-27
CA2488242A1 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
SE0104334D0 (sv) Therapeutic agents
PE20040534A1 (es) Medicamentos que comprenden tiofenos sustituidos y procedimientos para su preparacion
MXPA03011981A (es) 3-fluoruro-pirrolidinas como agentes antidiabeticos.
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
DE60315492D1 (de) Medizinisch verwendbare arylethanolamin verbindungen
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
KR970703333A (ko) 5-HT_1A 길항제로서의 피페라진 유도체(Piperazine derivatives as 5-HT_1A antagonists)
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
AR066460A2 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
ES2092890T3 (es) Aplicacion del riluzol en el tratamiento de la enfermedad de parkinson y de los sindromes de parkinson.
TNSN04165A1 (en) Substituted hydroxyethylamines
ATE302774T1 (de) Arzneimittel enthaltend betamimetika und ein neues anticholinergikum
DE602004006869D1 (de) 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit
GEP20022763B (en) 2-(3,5-Bis-Trifluoromethyl-Phenyl)-N-Methyl-N-(6-Morpholin-4-Yl-4-O-Tolyl-Pyridin-3-Yl)-Isobutyramide, Method for its Production and Medicament Containing the Same for Treatment of the Diseases Caused by NK-1 Receptor
AR046705A1 (es) Pirido-7-pirimidin-7-onas substituidas con hidroxialquilo
ATE361918T1 (de) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2- yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
SE8701375D0 (sv) Novel pyridyl- and pyrimidyl derivatives
BR9504375A (pt) Utilização de um composto formulação farmacêutica e método de tratamento
NZ533795A (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
IL162983A (en) Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis
AR041116A1 (es) Metodos para tratar pacientes que sufen el sindrome de piernas inquietas o desordenes relacionados
ATE295845T1 (de) Prucaloprid-n-oxid
BRPI0407212A (pt) 2-aminoimidazóis substituìdos, processos para a sua preparação, sua aplicação como medicamento ou diagnóstico bem como o medicamento contendo os mesmos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed